Cross-cultural Adaptation and Validation of the Simplified Chinese Version of the Copenhagen Neck Function Disability Scale

Study Design. A cross-sectional study. Objective. Th aim of this study was to translate and cross-culturally adapt Copenhagen Neck Function Disability Scale into a Simplified Chinese version (CNFDS-C), and evaluate the reliability and validity of CNFDS-C in patients with nonspecific chronic neck pain. Summary of Background Data. The CNFDS is a reliable and valid evaluation instrument for chronic neck pain. However, Simplified Chinese version of CNFDS hasn't been validated. Methods. A total of 150 participants were included in this study. Internal consistency was estimated according to Cronbach alpha. Test-retest reliability was assessed by intra-class correlation coefficient (ICC). Construct validity was analyzed by correlations between CNFDS-C and the Neck Disability Index (NDI), Visual Analogue Scale (VAS) as well as the short form (36) health survey (SF-36). Results. The original version of the CNFDS was cross-culturally adapted and translated into Simplified Chinese. CNFDS-C was indicated to have excellent reliability (Cronbach alpha = 0.810, ICC = 0.927). Moderate to substantial correlations between CNFDS-C and NDI (r = 0.642, P< 0.001), VAS (r = 0.581, P< 0.001), as well as Physical Function (r = -0.583, P<.001), Role Physical (r = -0.478, P< 0.001), Bodily Pain (r = -0.610, P< 0.001), and General Health (r = -0.439, P< 0.001) subscales of SF-36 were observed. Conclusion. CNFDS-C was demonstrated to have acceptable reliability and validity in patients with nonspecific chronic neck pain, which could be recommended for patients in Chinese mainland.

Automated summary

The study aims to translate and adapt CNFDS into Simplified Chinese version and evaluate its reliability and validity in patients with nonspecific chronic neck pain. The results indicate that CNFDS-C has excellent reliability and moderate to substantial correlations with other measures, suggesting it is a recommended tool for patients in Chinese mainland.